Q-Line Biotech Limited

growth strategy or external circumstances which may not be in our control. This may entail rescheduling and revising the funding requirement for a particular Object or increasing or decreasing the amounts earmarked towards any of the aforementioned Objects at the discretion of our management, subject to compliance with applicable law. The specific number and nature of equipment, plant and machinery to be procured and the work to be undertaken by our Company may change, depending on our business requirements, from time to time. Further, our proposed capacity expansion plan is subject to the risk of unanticipated delays in implementation and cost overruns.

## Details of Utilization of Net Proceeds

The details of utilization of the Net Proceeds are set forth herein below:

### 1. To Meet Working Capital Requirements

Our business requires working capital majorly for investment in trade receivables, inventories and payment to trade payables and funding day to day operations. Our Company is engaged in the business of manufacturing, trading and distribution of Reagents, medical equipment's for our customers located in India and outside India.

The Company will meet the requirement to the extent of ₹ 11000.00 lakhs from the Net Proceeds of the Issue and balance from internal accruals and borrowings, if any, at an appropriate time.

Details of Estimation of Working Capital requirement on standalone basis are as follows:

(₹ In Lakhs)

<table><thead><tr><th rowspan="2">S. No.</th><th rowspan="2">Particulars</th><th colspan="5">(₹ In Lakhs)</th></tr><tr><th>March 31, 2023</th><th>March 31, 2024</th><th>March 31, 2025</th><th>March 31, 2026</th><th>March 31, 2027</th></tr><tr><th></th><th></th><th colspan="3">Restated</th><th colspan="2">Projected</th></tr></thead><tbody><tr><td></td><td><strong>Current Assets</strong></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>a)</td><td>Inventories</td><td>4,359.44</td><td>10,521.99</td><td>9,021.34</td><td>13,286.87</td><td>15863.70</td></tr><tr><td>b)</td><td>Trade Receivables</td><td>3,305.76</td><td>2,644.36</td><td>8,277.64</td><td>11,028.22</td><td>15540.85</td></tr><tr><td>c)</td><td>Short-Term Loans and Advances</td><td>934.33</td><td>3,779.90</td><td>3,210.05</td><td>4,158.00</td><td>5280.66</td></tr><tr><td>d)</td><td>Other Current Assets</td><td>9.59</td><td>15.87</td><td>1,219.53</td><td>2,246.37</td><td>3,632.60</td></tr><tr><td></td><td><strong>Total - Current Assets (I)</strong></td><td><strong>8,609.12</strong></td><td><strong>16,962.12</strong></td><td><strong>21,728.56</strong></td><td><strong>30,719.46</strong></td><td><strong>40,317.82</strong></td></tr><tr><td></td><td><strong>Current Liabilities</strong></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>a)</td><td>Trade payables</td><td>3,970.62</td><td>5,919.56</td><td>5,562.99</td><td>6545.77</td><td>6431.30</td></tr><tr><td>b)</td><td>Other current liabilities</td><td>612.71</td><td>1,662.30</td><td>2,491.71</td><td>2,964.90</td><td>2997.68</td></tr><tr><td>c)</td><td>Short-term provisions</td><td>297.48</td><td>258.01</td><td>1,599.67</td><td>2,065.52</td><td>2912.61</td></tr><tr><td></td><td><strong>Total - Current Liabilities (II)</strong></td><td><strong>4,880.81</strong></td><td><strong>7,839.87</strong></td><td><strong>9,654.37</strong></td><td><strong>11,576.19</strong></td><td><strong>12,341.60</strong></td></tr><tr><td></td><td><strong>Net Working Capital Requirement (III)</strong></td><td><strong>3,728.31</strong></td><td><strong>9,122.25</strong></td><td><strong>12,074.19</strong></td><td><strong>19,143.27</strong></td><td><strong>27976.22</strong></td></tr><tr><td></td><td><strong>Funding Pattern</strong></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>a)</td><td>Short Term Borrowings/Internal Accrual</td><td>3,728.31</td><td>9,122.25</td><td>12,074.19</td><td>14,143.27</td><td>21976.22</td></tr><tr><td>b)</td><td><strong>IPO Proceeds</strong></td><td><strong>NIL</strong></td><td><strong>NIL</strong></td><td><strong>NIL</strong></td><td><strong>5000.00</strong></td><td><strong>6000.00</strong></td></tr></tbody></table>

### Assumptions for working capital requirements

The following table sets forth the details of the holding period (with days rounded to the nearest whole number) considered for the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023, as well as estimated for financial year ended March 31, 2026 and March 31, 2027.

<table><thead><tr><th rowspan="2">Particulars</th><th rowspan="2">Unit</th><th>March 31, 2023</th><th>March 31, 2024</th><th>March 31, 2025</th><th>March 31, 2026</th><th>March 31, 2027</th></tr><tr><th>Audited</th><th>Audited</th><th>Audited</th><th colspan="2">Estimated</th></tr></thead><tbody><tr><td>Debtors</td><td>Days</td><td>66.0</td><td>47</td><td>96</td><td>120</td><td>127</td></tr><tr><td>Creditors</td><td>Days</td><td>150</td><td>139</td><td>155</td><td>60</td><td>50</td></tr><tr><td>Inventory</td><td>Days</td><td>180</td><td>413</td><td>226</td><td>247</td><td>241</td></tr></tbody></table>

**Justification:**

88